Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 1403 Nifty 500 stocks· EOD 2026-06-19

Nath Bio-Genes (India) Limited

NATHBIOGEN · NSE · Basic Materials

₹160.78
-11.23 (-6.53%)
Buy zoneSell
The bottom line

StocksWizard rates Nath Bio-Genes (India) Limited a Sell, scoring 40/100 on our blended model. At ₹160.78 it trades below our blended DCF and relative-multiples fair value of ₹321.56, implying roughly 100% upside to that estimate — we read the stock as undervalued by 100%. Financial health scores 18/100 (grade F), in the distress band on the Altman Z-score, with a Piotroski F-score of 1/9. It clears 5 of 12 investability checks, with durability 46, valuation 100 and momentum 50 on our 0–100 scales.

These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Our verdictSolvency risk
Sell40/100
Quality46
Valuation100
Momentum50
Financial trend23
Intrinsic value
Our fair value
₹321.56
Undervalued by 100%
Price ₹160.78Range ₹182.1₹347.28

With a 20% margin of safety, our buy-below price is ₹257.25. Low-confidence estimate — limited data.

F
Financial health 18/100
Altman Z 1.72 · Distress zone

Piotroski F-score 1/9 — quality of earnings & balance sheet.

Investability checklist

Passed 5 of 12 checks42/100
  • ROE above 15%6.3%
  • Low debt (D/E < 0.5)0.20x
  • Positive free cash flow
  • Revenue growth > 10%-1%
  • Earnings growing
  • Net margin ≥ 10%9.4%
  • Current ratio > 1.51.97
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zoneZ 1.72
  • Piotroski ≥ 71/9

1-year price

EOD · 2026-06-19
1W
-3.4%
1M
-5.7%
3M
+14.5%
6M
+5.3%
1Y

Our scores

Durability46
Valuation100
Momentum50

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Quarterly results

4Q2019₹33 Cr revenue
Net profit ₹4 Cr12% margin
1Q2020₹60 Cr revenue
Net profit ₹8 Cr13% margin
2Q2020₹193 Cr revenue
Net profit ₹41 Cr21% margin
3Q2020₹24 Cr revenue
Net profit ₹3 Cr13% margin
Revenue Net profitLatest revenue QoQ -88%

Shareholding

Promoter61.7%
Institutions0.0%
Public & other38.3%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹306 Cr
P/E ratio
7.7
P/B ratio
0.53
EPS (TTM)
₹20.98
ROE
6.3%
Debt / Equity
0.20x
Profit margin
9.4%
Free cash flow
₹-63 Cr
52-week high
₹232.15
-30.74% from high
52-week low
₹129.02
Dividend yield
Beta
0.82

SWOT snapshot

Strengths

  • Lightly leveraged balance sheet.

Weaknesses

  • Low return on equity (6.3%).
  • Weak Piotroski score (1/9).

Opportunities

  • Trading in our value buy zone versus sector peers.
  • Trades ~100% below our estimated fair value.

Threats

  • Balance-sheet stress — Altman Z 1.72.

About Nath Bio-Genes (India) Limited

Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; plant nutrient supplements; pearl millets; seeds for field crops, such as bajra, maize, corn, paddy, wheat, and jowar; and seeds for vegetables comprising chilli, okra, tomato, bitter gourd, and c

More in Basic Materials

All stocks

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.